1
Q

Survival rate of lung cancer

A

Very low, 1 and 5 year survival.

Due to patients presenting late with advanced stages.

Symptoms are also very similar to those who already smoke.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Causes of lung cancer

A

90% caused by smoking.

Lung cancer deaths in women increasing despite those in men decreasing.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

General Symptoms

A

Usually in smoker >20 years

Respiratory:
Cough
Haemoptysis (red flag)
Dyspnoea
Wheeze
Chest pain (more advanced stage)
Hoarseness
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Common systemic and metastatic symptoms

A

Weight loss

Anorexia, nausea

Malaise

Fatigue

Secondary site: CNS, bone and skin (i.e pain and masses).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Paraneoplastic syndromes

A

Hyponatremia

Hypercalcaemia

Less commonly: itching, gynaecomastia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Sub-types of lung cancer

A

Non-small cell:
Squamous- central, cavitation, hypercalcaemia.

Adenocarcinoma: peripheral lung, more common in non-smokers.

Small cell:
central
early lymphatic spread.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Common signs of lung cancer seen in examination

A

Clubbing

Cachexia- muscle wasting

Supraclavicular/ cervical lymphadenopathy

Stridor

Lung collapse/ pleural effusion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Investigations to confirm diagnosis and determine tumour type/ extent

A

CT

Biopsy:

  • Bronchoscopy.
  • Endobronchial ultrasound- needle aspiration.
  • Percutaneous CT thorax
  • P eripheral lymph node/liver

Complete staging:
PET scanning- glucose analogue shows areas of high uptake, locates cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Staging in lung cancer

A

Takes into account:

  • Tumour size
  • Involvement of any local structures and invasion
  • Lymph/ blood metastases.

TNM staging
T- size and invasion
N- nodal stage
M- metastasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Surgery non small cell lung cancer

A

Considered in all patients with stage 1/2

Lobectomy or even pneumonectomy (whole lung removal)

Radical radiotherapy with or without chemotherapy- given to stage 1/2 who are not fit enough/ unwilling to do surgery.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Palliative radiotherapy- in NSCLC

A
Relieves symptoms like:
- haemoptysis
- Intractable cough
- Dyspnoea
 but not expected to cure.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Small cell lung cancer treatment

A

Chemotherapy is primary- more effective than in NSCLC

Controls symptoms and can induce remission

Prolongs survival by months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Small cell carcinoma

A

Accounts for 10-15% of lung cancers.

Present very darkly in microscope as they are mainly nucleus.

Little cytoplasm

Salt and pepper chromatin in nuclei.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Squamous cell carcinoma

A

Central origin

Cigarette smoke stimulates squamous metaplasia then dysplasia of bronchial epithelium.

Accounts for 20-30% of NSCC- second most common type

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Adenocarcinoma

A

Most common type of non-small cell carcinoma- around glands

Typically happen at periphery of the lung.

Fibrotic: the cells make fibrotic protein

Tissues can be stained to look for specific proteins: TTF1 most typical.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Mutations targeted in adenocarcinoma

A

Key mutations in adenocarcinoma:
EGFR
ALK
PD1/ PD-L1

These mutations are targeted with specific agent.

New treatment that can be used to treat adenocarcinomas.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Spread of lung cancer

A

Local and direct:
Adjacent lung
Pleura and pleural cavity.

Lymphatic:
Pulmonary lymphatics
Lymph nodes- hilar and mediastinal.

Systemic:
Liver
Bone
Brain
Adrenal
18
Q

Erlotinib

A

Tyrosine kinase inhibiting agent that targets epidermal growth factor receptor mutations (EGFR)

19
Q

Gefitinib

A

Tyrosine kinase inhibiting agent that targets epidermal growth factor receptor mutations (EGFR)

20
Q

Why are survival rates for lung cancer so poor?

A

Patients present late with advanced stage lung cancer

Due to early symptoms being similar to those who smoke.

21
Q

Hyponatraemia

A

Increased retention of sodium in the blood.

This is a paraneoplastic syndrome in small cell carcinoma due to SIADH- increased secretion of ADH.

22
Q

Hypercalcaemia

A

Too much calcium in the blood.

A paraneoplastic symptom in in sqaumous cell carcinoma.

Caused by an increase in Parathyroid hormone activity.

23
Q

Associations linked to lung cancer

A

Smoking

Fibrosing alveolitis

Ionising radiation

Air pollution

Chromium

Iron oxide

Nickel

Mesothelioma

24
Q

Surgical considerations for lung cancer

A

The operative mortality

Cardiovascular morbidity

Effect on lung function

Post-op quality of life

Post-op radiotherapy?

Chemotherapy?

The actual surgical approach?

25
The three types of resection in lung cancer
Wedge resection- remove small part of a lobe. Lobectomy Pneumonectomy
26
Effects of ionising radiation (seen in radiotherapy)
Double/ single strand DNA break. Base damage Cross links between DNA, proteins and strands. Cell death
27
Chromosomal breaks
Can be caused by ionising radiation. Causes early apoptosis
28
Chromosomal aberrations
Abnormal structure of chromosomal that can be caused by radiotherapy. This causes: Mitotic death Reproductive death Late apoptosis.
29
Radical treatment options for locally advanced lung cancer
Cancer treatments with aims to cure rather than palliate. Options: - Radiotherapy +/- chemotherapy. - Chemo, radiotherapy + surgery. - Chemo + consolidation radiotherapy (small cell)
30
Radiation pneumonitis
Lung disease that is induced by radiation- i.e radiotherapy Fibrosis can occur in the late stage of the disease
31
Palliative chemotherapy
Chemotherapy with aims of reducing symptoms, not curing. Increases survival by around 8 months in NSCLC. In limited stage SCLC, increases survival by 16-24 months. In extensive stage- 6-12 months.
32
Uses of palliative radiotherapy
Uses to relieve symptoms associated with lung cancer metastasis: ``` Bone pain Spinal cord compression SVC obstruction- stent placed Brain metastasis Haemoptysis. ```
33
Personalised therapy for palliative care
Creating therapy based on tumour gene expression. Mutations targeted- i.e EGFR, ALK
34
EGFR inhibitor
Cancer therapy used to target EGFR mutations. Can be: Tyrosine-kinase inhibitors Antibodies specific to EGFR
35
Immunotherapy for lung cancer
Immune checkpoint inhibitors: - PD-L1 antibodies. Prevent immune response from being suppressed. Used for NSCLC. - Nivolumab - Pembrolizumab Therapeutic vaccines- stimulate the body to attack tumour specific antigens.
36
Nivolumab
Immune checkpoint inhibitor that is used in squamous cell carcinoma Used second line
37
Pembrolizumab
Immune checkpoint inhibitor used for lung cancer.
38
The normal immune surveillance of a tumour
1. Tumours contain antigens which are presented by dendritic cells. 2. This activates T-cells in the lymph node- produces CD4 and CD8 3. CD4 help to further activate CD8 cells which release chemicals to kill tumour. Includes perforin, granzyme, IFN-gamma.
39
PD-L1 on tumours
PD-L1 is a co-inhibitory molecule that decreases T-cell mediated responses Allows tumour to evade immune system
40
Co-stimulatory molecules
Found on antigen presenting cells- promote immune response in T cells. Examples: CD80/86 CD28
41
Co-inhibitory molecules
Dampen T cell-mediated responses- avoids damaging the body during infections. Examples: CTLA-4 + PD-I (receptors) PD-L1/2- on APCs
42
Neo-adjuvant chemotherapy
Chemotherapy taken before surgical tumour resection. Examples: gemcitabine and carboplatin.